錢雪明博士是創勝集團醫藥有限公司（下稱創勝集團）的首席執行官。創勝集團是一家具備生物藥發現、研發、工藝開發和生產全流程整合能力的臨床階段的生物制藥公司。2021年9月29日，創勝集團在香港聯合交易所主板上市，股票代碼：06628。
錢雪明博士畢業于復旦大學生物物理學系 (1985 – 1990)，并分別在哥倫比亞大學 (Columbia University, 1990 – 1992) 和奧爾巴尼醫學中心 (Albany Medical Center, 1995 – 1997) 獲得神經學與生理學碩士學位和神經學與藥理學博士學位。
錢雪明博士擁有 20 年的生物制藥行業經驗。在創立創勝集團之前，錢博士于 2010-2013 年間任盛諾基醫藥集團 (Shenogen Pharma Group) 研發總裁和董事會成員。1997-2010 間任職于美國安進公司，專注于抗體新藥的開發。錢博士是十多個創新藥物專利申請的發明人，也是國際抗體協會會員、國際腎病協會會員、新藥創始人俱樂部、創新生物社和 BayHelix 百華協會會員，獲得了國家級高層次人才、蘇州工業園區科技領軍人才和蘇州市姑蘇創新創業領軍人才等支持。
Dr. Xueming Qian is the CEO of Transcenta Holding Limited (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics.?
Dr. Qian received his B.S. in Biophysics from Fudan University (Shanghai, China, 1985 – 1990), M.A. in Neuroscience/Physiology from Columbia University (New York, USA, 1990 – 1992) and Ph.D. in Neuroscience and Pharmacology from Albany Medical Center (New York, USA, 1995 – 1997).
Dr. Qian has over twenty years of industrial experience in biotechnology drug discovery and development. Before starting Transcenta, Dr. Qian was Senior VP and R&D Head of Shenogen Pharma Group from 2010 and 2013. Dr. Qian worked more than 12 years at Amgen as principal scientist and project team leader from 1997 and 2010. Dr. Qian is the author over ten patent applications and a member of the New Drug Founder’s Club, Bio-logics Innovation Group, BayHelix as well as several scientific organizations such as ASCO, ESMO, AACR, ASN and Antibody Society.?